 |
| (사진= 연합뉴스 제공) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Celltrion announced on the 21st that nothing has been confirmed about the acquisition of the biopharmaceutical division of the US medical device company Baxter International.
This division develops and commercializes medicines such as biopharmaceuticals and vaccines. However, an official from Celltrion said, "We have reviewed the acquisition of the biopharma solution business, but nothing has been confirmed at the moment." "If a decision is made on the matter, we will re-publicize it and announce the progress in the future within a month," he said. Celltrion signed a contract with Baxter's Biomedicine Commissioned Production (CMO) division in 2017 to produce Ramshima, an autoimmune disease treatment.
AlphaBIZ 폴리(hoondork1977@alphabiz.co.kr)
